INTERACTIVE: Merck sells Kyorin rights to overactive bladder drug
This article was originally published in Scrip
Executive Summary
Merck has sold its unwanted overactive bladder drug, Vibegron, to Kyorin for an undisclosed sum. To find out more about the deal, click on the options in the spider diagram below.